Correction: Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case

Publicado 2019

Plasma HER2ECD a promising test for patient prognosis and prediction of response in HER2 positive breast cancer: results of a randomized study - SAKK 22/99

por Eppenberger-Castori, Serenella, Klingbiel, Dirk, Ruhstaller, Thomas, Dietrich, Daniel, Rufle, Daniel Alexander, Rothgiesser, Karin, Pagani, Olivia, Thürlimann, Beat
Publicado 2020

Predicting Effects of Clinicopathological Variables on Her2 Gene Amplification by Chromogenic in situ Hybridization (CISH) in IHC Her2 (2+) Breast Cancer Patients; A Study from Iran

por Hashemi Bahremani, Mohammad, Ebrahimi, Abdolali, Fallahi, Mohaddese
Publicado 2020

Biasing human epidermal growth factor receptor 4 (HER4) tyrosine kinase signaling with antibodies: Induction of cell death by antibody‐dependent HER4 intracellular domain trafficking

por Lanotte, Romain, Garambois, Véronique, Gaborit, Nadège, Larbouret, Christel, Musnier, Astrid, Martineau, Pierre, Pèlegrin, André, Chardès, Thierry
Publicado 2020

Multi-omics analyses identify HSD17B4 methylation-silencing as a predictive and response marker of HER2-positive breast cancer to HER2-directed therapy

por Yamashita, Satoshi, Hattori, Naoko, Fujii, Satoshi, Yamaguchi, Takeshi, Takahashi, Masato, Hozumi, Yasuo, Kogawa, Takahiro, El-Omar, Omar, Liu, Yu-Yu, Arai, Nobuaki, Mori, Akiko, Higashimoto, Hiroko, Ushijima, Toshikazu, Mukai, Hirofumi
Publicado 2020

Pathological complete response to neoadjuvant trastuzumab and pertuzumab therapy is related to human epidermal growth factor receptor 2 (HER2) amplification level in HER2-amplified breast cancer

por Choi, Jin Hyuk, Jeon, Chang Wan, Kim, Young Ok, Jung, Sungui
Publicado 2020

Phase Ib Trial of Copanlisib, A Phosphoinositide-3 Kinase (PI3K) Inhibitor, with Trastuzumab in Advanced Pre-Treated HER2-Positive Breast Cancer “PantHER”

por Keegan, Niamh M., Furney, Simon J., Walshe, Janice M., Gullo, Giuseppe, Kennedy, M. John, Smith, Diarmuid, McCaffrey, John, Kelly, Catherine M., Egan, Keith, Kerr, Jennifer, Given, Mark, O’Donovan, Peter, Hernando, Andres, Teiserskiene, Ausra, Parker, Imelda, Kay, Elaine, Farrelly, Angela, Carr, Aoife, Calzaferri, Giulio, McDermott, Ray, Keane, Maccon M., Grogan, Liam, Breathnach, Oscar, Morris, Patrick G., Toomey, Sinead, Hennessy, Bryan T.
Publicado 2021

Axillary response according to neoadjuvant single or dual human epidermal growth factor receptor 2 (HER2) blockade in clinically node‐positive, HER2‐positive breast cancer

por Cha, Chihwan, Ahn, Sung Gwe, Kim, Dooreh, Lee, Janghee, Park, Soeun, Bae, Soong June, Kim, Jee Ye, Park, Hyung Seok, Park, Seho, Kim, Seung Il, Park, Byeong‐Woo, Jeong, Joon
Publicado 2021

Specific HER2 Exon 20 Gly776 Deletion-Insertions in Non-Small Cell Lung Cancer: Structural Analysis and Sensitivity to HER2-Targeted Tyrosine Kinase Inhibitors

por Yang, Guangjian, Xu, Haiyan, Hu, Jiaqi, Liu, Runze, Hu, Peizeng, Yang, Yaning, Li, Weihua, Hao, Xuezhi, Zhang, Shuyang, Xu, Fei, Ai, Xin, Li, Junling, Wang, Yan
Publicado 2022

Identification of Immunogenic MHC Class II Human HER3 Peptides that Mediate Anti-HER3 CD4(+) Th1 Responses and Potential Use as a Cancer Vaccine

por Basu, Amrita, Albert, Gabriella K., Awshah, Sabrina, Datta, Jashodeep, Kodumudi, Krithika N., Gallen, Corey, Beyer, Amber, Smalley, Keiran S.M., Rodriguez, Paulo C., Duckett, Derek R., Forsyth, Peter A., Soyano, Aixa, Koski, Gary K., Lima Barros Costa, Ricardo, Han, Heather, Soliman, Hatem, Lee, Marie Catherine, Kalinski, Pawel, Czerniecki, Brian J.
Publicado 2022

Breast Carcinoma – A Comparative Study of Immunohistochemistry and Fluorescence in Situ Hybridization for Her-2 Assessment and Association of ER, PR, HER-2 and Ki-67 Expression with Clinico-Pathological Parameters

por K, Sajitha, Arumugam, Meenakshi, Shetty, Jayaprakash, Shetty, Reshma A, Asani, Ritu, Shetty, Prashanth D
Publicado 2022

Exploring the relationships between hormone receptor, HER2 status, and bone involvement in the first distant metastases of in Chinese breast cancer patients who lacked HER2 targeted therapy

por Jia, Zhifeng, Dai, Muwei, Shang, Yuguang, Li, Yue, Li, Zhensheng
Publicado 2023

Type of adjuvant endocrine therapy and disease-free survival in patients with early HR-positive/HER2-positive BC: analysis from the phase III randomized ShortHER trial

por Dieci, Maria Vittoria, Bisagni, Giancarlo, Bartolini, Stefania, Frassoldati, Antonio, Vicini, Roberto, Balduzzi, Sara, D’amico, Roberto, Conte, Pierfranco, Guarneri, Valentina
Publicado 2023

Identifying HER2 from serum‐derived exosomes in advanced gastric cancer as a promising biomarker for assessing tissue HER2 status and predicting the efficacy of trastuzumab‐based therapy

por Li, Qian, Lv, Minzhi, Lv, Lihua, Cao, Nida, Zhao, Aiguang, Chen, Jiayan, Tang, Xi, Luo, Rongkui, Yu, Shan, Zhou, Yan, Cui, Yuehong, Guo, Wei, Liu, Tianshu
Publicado 2022

Launching the European Laboratory project: Britain's importance to it, and the obstacles to her participation in 1950

por Krige, Gerhard John
Publicado 1984

Her Excellency Ms Ana Brnabic Prime Minister Government of the Republic of Serbia

por Ordan, Julien Marius
Publicado 2018

Her Excellency Ms Asako Omi Vice-Minister for Foreign Affairs Japan

por Ordan, Julien
Publicado 2020

HER2-Positive Metastatic Breast Cancer: Available Treatments and Current Developments

por Essadi, Ismail, Benbrahim, Zineb, Kaakoua, Mohamed, Reverdy, Thibaut, Corbaux, Pauline, Freyer, Gilles
Publicado 2023

Sacituzumab Govitecan in HR-positive HER2-negative metastatic breast cancer

por Nardin, Simone, Del Mastro, Lucia
Publicado 2023